Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma in the United States

The results of a recent single-arm trial (ZUMA-5) of axicabtagene ciloleucel (axi-cel) for relapsed/refractory (r/r) FL demonstrated high rates of durable response and tolerable toxicity among treated patients. To quantify the value of axi-cel compared to standard of care (SOC) to manage r/r FL patients who have had at least two prior lines of systemic therapy (3L+), a cost-effectiveness model was developed from a US third-party payer perspective.

Source: Value in Health - April 16, 2024 Category: International Medicine & Public Health Authors: Olalekan O. Oluwole, Markqayne D. Ray, Katherine L. Rosettie, Graeme Ball, Jorge Jacob, S. Pinar Bilir, Anik R. Patel, Caron A. Jacobson Source Type: research